Company Overview
YD Bio Ltd functions as a biopharmaceutical entity dedicated to advancing blood-based cancer detection methodologies and developing stem cell- and exosome-based therapeutics aimed at addressing a spectrum of diseases with significant unmet medical needs. Operating within the healthcare sector and specifically the biotechnology industry, the company positions itself to leverage biological innovations for therapeutic development and diagnostic solutions. The organization maintains a market capitalization of $438.29M and generated annual revenue of $510,360 in the trailing twelve months, while its employee count is not publicly disclosed. These financial figures indicate that the company operates with a substantial valuation relative to its current revenue stream, suggesting a market premium often associated with early-stage biotechnology firms where future pipeline potential outweighs current profitability. The disparity between the multi-hundred-million dollar market cap and the modest revenue highlights that investor valuation is driven primarily by the perceived long-term potential of its therapeutic and diagnostic platforms rather than immediate cash generation.
Financial Health
The company reported revenue of $510,360 over the trailing twelve months, yet it recorded a net income of $-1,411,559 and an EBITDA of $-1,357,195, revealing a cost structure where expenses significantly exceed operational revenue. The free cash flow stands at $-3,875,569, which indicates that the company is currently burning cash to fund research, development, and commercialization efforts, thereby limiting its immediate financial flexibility for external expansion or acquisitions. Gross margin is calculated at 30.4%, demonstrating that the company retains a reasonable portion of revenue after direct production costs, while the operating margin of -444.6% and profit margin of -276.6% reflect the heavy overheads typical of biotechnology firms in the research and development phase. Total cash on hand is $3.13M, which is substantially higher than the total debt of $22,265, and the debt-to-equity ratio of 0.34 suggests a balance sheet that is not leveraged but rather carries minimal debt obligations relative to equity. The current ratio of 13.18 indicates an exceptionally strong position regarding short-term liquidity, as current assets are more than thirteen times greater than current liabilities. Furthermore, the return on equity of -42.7% and return on assets of -25.4% reveal that, while the company is profitable in nominal terms due to non-operating income or specific accounting adjustments, its core management effectiveness in generating returns from shareholder equity and asset base remains negative due to the substantial net losses incurred.
Valuation Assessment
Trailing P/E and forward P/E are both listed as N/A, which implies that traditional earnings-based valuation metrics are unavailable due to the company's consistent net losses, making the difference between these figures irrelevant for assessing an earnings trajectory that does not yet exist. The price-to-book ratio is 1.36, indicating that the market values the company at a 36% premium over its book value, a scenario common in biotech sectors where intangible assets and intellectual property are not fully captured on the balance sheet. The price-to-sales ratio is 858.79, and the EV/EBITDA is -3.51, suggesting that alternative valuation metrics are heavily skewed by the lack of profitability and high revenue multiples relative to sales, which points to a valuation model reliant on future growth expectations rather than current cash flows. The 52-week high is $25.00 and the 52-week low is $5.30, meaning the current trading price sits within this wide range, though the exact percentage below the high depends on the real-time price which fluctuates. The beta value is 0.17, which signifies that the stock's price volatility is significantly lower than the broader market, suggesting that the stock moves less dramatically in response to general market swings compared to large-cap equities.
Growth & Income
Revenue growth year-over-year is 95.6%, whereas earnings growth is N/A, indicating that while the top line is expanding rapidly, the bottom line remains in a loss position, implying that revenue growth is not yet translating into proportional profit growth due to high fixed costs. As a non-dividend payer, the company does not distribute a dividend yield, and the payout ratio is 0.0%, which confirms that the firm retains all earnings and reinvests resources directly into research and development rather than paying dividends to shareholders. The overall growth and income profile is characterized by aggressive revenue expansion without current profitability, relying on the assumption that future product approvals or sales will eventually convert these losses into sustainable earnings. The absence of a dividend yield combined with high negative free cash flow underscores a strategy focused entirely on capital appreciation and pipeline development rather than current income generation.